PharmaEngine

PharmaEngine OCF Margin

The Operating Cash Flow Margin of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 189.47 %. In the previous year, Operating Cash Flow Margin was 18.10 % — a change of 946.76% (higher).

OCF Margin

189.47 %

YoY

946.76%

Last updated:

Operating Cash Flow Margin of PharmaEngine is 2025 189.47 % . Operating Cash Flow Margin of PharmaEngine was 2024 18.10 % . It decreases by 946.76% higher compared to the previous year.

The PharmaEngine OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
253.97 TWD
Jan 1, 2019
5.12 TWD
Jan 1, 2020
6.13 TWD
Jan 1, 2021
141.97 TWD
Jan 1, 2022
30.87 TWD
Jan 1, 2023
33.47 TWD
Jan 1, 2024
18.10 TWD
Jan 1, 2025
189.47 TWD
The PharmaEngine OCF Margin history
YEAROCF MarginYoY
189.47 %+946.76%
18.10 %-45.93%
33.47 %+8.43%
30.87 %-78.26%
141.97 %+2,214.72%
6.13 %+19.80%
5.12 %-97.98%
253.97 %-738.98%
-39.75 %-151.82%
76.70 %-13.16%
88.32 %+54.28%
57.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Operating Cash Flow Margin of PharmaEngine is 189.47 % in 2025.

Operating Cash Flow Margin of PharmaEngine changed from 18.10 % to 189.47 %, representing a 946.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's PharmaEngine with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — PharmaEngine

All Key Metrics — PharmaEngine